Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012).

MLA

Ammann, Eric M., et al. “Self-Controlled Assessment of Thromboembolic Event (TEE) Risk Following Intravenous Immune Globulin (IGIV) in the U.S. (2006-2012).” Journal of Thrombosis and Thrombolysis, vol. 53, no. 2, Feb. 2022, pp. 264–72. EBSCOhost, https://doi.org/10.1007/s11239-021-02610-4.

APA

Ammann, E. M., Chrischilles, E. A., Carnahan, R. M., Fireman, B., Fuller, C. C., Schweizer, M. L., Garcia, C., Pimentel, M., Leonard, C. E., Baker, M. A., Cuker, A., Leira, E. C., Robinson, J. G., & Winiecki, S. K. (2022). Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012). Journal of Thrombosis and Thrombolysis, 53(2), 264–272. https://doi.org/10.1007/s11239-021-02610-4

Chicago

Ammann, Eric M, Elizabeth A Chrischilles, Ryan M Carnahan, Bruce Fireman, Candace C Fuller, Marin L Schweizer, Crystal Garcia, et al. 2022. “Self-Controlled Assessment of Thromboembolic Event (TEE) Risk Following Intravenous Immune Globulin (IGIV) in the U.S. (2006-2012).” Journal of Thrombosis and Thrombolysis 53 (2): 264–72. doi:10.1007/s11239-021-02610-4.